Select
Home
About Us
Company Overview
Management Team
Board of Directors
Scientific Advisory Board
Corporate Governance
Development
Assets in Development
Deoxymab 3E10
PAT SC1
Investors
Analysts Reports
Annual Reports
Financial Reports 2020
Financial Reports 2019
Financial Reports 2018
Financial Reports 2017
Financial Reports 2016
News & Media
Market Announcements 2020
Market Announcements 2019
Market Announcements 2018
Market Announcements 2017
Newsletters
In the Media
Media Contact
Contact
ASX: PAB
LATEST NEWS
16 March 2020
PAT-DX1 Novel Mechanism for Crossing the Blood Brain Barrier Confirmed
2 March 2020
PAT-DX1-NP Crosses Blood Brain Barrier and Targets Tumours
20 January 2020
PAT-DX1 to be Showcased at International Conference
DEOXYMAB 3E10 INTRODUCTION
DEOXYMAB 3E10 PLATFORM
